BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED ® technology and materials, yesterday held its Virtual 2022 Annual Meeting of Shareholders.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they will be attending the Metals in Medicine Gordon Research Conference focusing on Advancing the Use of Metal-Based Compounds and Nanotheranostics for Personalized Medicine.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data from clinical programs evaluating maralixibat (LIVMARLI®) in patients with Alagille syndrome at the 54th Annual ESPGHAN Meeting.

Gemina Laboratories Ltd. is pleased to announce that the Company has entered into an agency agreement dated June 23, 2022 with Leede Jones Gable Inc.

Multiple FDA - IND applications are expected to be filed soon. Interested Accredited investors are highly invited.

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data at the annual meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) being held in Copenhagen, Denmark.

Quotient Limited announced the pricing of an underwritten public offering of 66,666,667 ordinary shares and ordinary share equivalents for aggregate gross proceeds of $20.0 million.

Daewoong announced that the U.S. Food and Drug Administration (FDA) had approved the IND for the phase 2 clinical trial of DWN12088, a PRS (Prolyl-tRNA Synthetase) inhibitor for patients with idiopathic pulmonary fibrosis.